

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.		
		Filing Date April 28, 2006	Group Art Unit 1643	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/L.B./	1	2006/0058511	03/16/2006	Tanikawa <i>et al.</i>			
↓	2	2009/0214535	08/27/2009	Igawa <i>et al.</i>			
↓	3	2009/0297501	12/03/2009	Igawa <i>et al.</i>			
↓	4	2010/0015133	01/21/2010	Igawa <i>et al.</i>			

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
/L.B./	5	EP 1 327 681	07/16/2003	Europe			
↓	6	WO 01/79494	10/25/2001	WIPO			
↓	7	WO 02/33072	04/25/2002	WIPO			
↓	8	WO 02/33073	04/25/2002	WIPO			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/L.B./	9	ABE <i>et al.</i> , "Surrogate thrombopoietin," <i>Immunology Letters</i> , 61:73-78 (1998)
↓	10	CREIGHTON, "Protein folding," <i>Biochem. J.</i> , 270(1):1-16 (1990)
↓	11	DENG <i>et al.</i> , "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , 92:1981-1988 (1998)
↓	12	ELLIOTT <i>et al.</i> , "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996)
↓	13	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
↓	14	KONTERMANN, R., "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26(1):1-9 (2005)
↓	15	PALACIOS <i>et al.</i> , "IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo," <i>Cell</i> , 41:727-734 (1985)
↓	16	SOUYRI, "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)
↓	17	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
↓	18	International Search Report for App. Ser. No. PCT/JP2004/008585, mailed September 7, 2004, 4 pages
↓	19	International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/008585, 10 pages

Examiner Signature <i>/Lynn Bristol/</i>	Date Considered 05/27/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1643

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/L.B./	20	European Search Report for App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages
/L.B./	21	U.S. EXAMINER SHULAMITH H. SHAFFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 13 pages

Examiner Signature  /Lynn Bristol/	Date Considered  05/27/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	